Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Научный центр психического здоровья РАМН, Москва; 2Первый Московский государственный медицинский университет им. И.М.Сеченова
• депрессивный эпизод, умеренный (F32.1) или тяжелый без психотических симптомов (F32.2) – 25,4% (72 наблюдения); • рекуррентное депрессивное расстройство, умеренный или тяжелый депрессивный эпизод (F33.1,F33.2) – 66,8% (189 наблюдений); • биполярное аффективное расстройство (F31), умеренный или тяжелый депрессивный эпизод (F31.3, F31.4) – 7,8% (22 наблюдения).
Список исп. литературыСкрыть список 1. Доклад Рабочей группы CINP на основе обзора доказательных данных. Терапия антидепрессантами и другие методы лечения депрессивных расстройств. М., 2008: 43–135. 2. Левин Я.И. Современная сомнология. Психические расстройства в общей медицине. М., 2007; 4: 61–72. 3. Мосолов С.Н. Сравнительные полисомнографические характеристики больных биполярными фазно протекающими психозами с частыми («быстрые циклы») и редкими обострениями. Соц. и клин. психиатр. 1992; 3: 20–9. 4. Armstrong SM, McNulty OM, Guardiola-Lemaitre B et al. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993; 46: 45–9. 5. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 2000; 25: 446–58. 6. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126–33. 7. Fahndrich E, Haug HJ. Diurnal variation of mood in psychiatric patients of different nosological groups. Neuropsychobiol, 1998, 20: 141–4. 8. Ford DE, Kamerow DB. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262: 1479–84. 9. Goodwin G, Rouillon F, Emsley R. Eur Neuropsychopharmacol 2008; 18 (suppl4): S338. 10. Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev 2004; 8: 19–30. 11. Kasper S, Laiglé L, Bayle F. Eur Neuropsychopharmacol 2008; 18 (suppl. 4): S336. 12. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 13. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 14. Loo H, Hale A, D\'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-НТ2С antagonist, in the treatment of major depressive disorder: a placebocontrolled dose range study. Int J Clin Psychopharmacol 2002; 17: 239–47. 15. Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000; 4: 253–62. 16. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819–34. 17. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533–59. 18. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 19. Mouret J, Lemoine P, Minuit MP et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology (Berl) 1988; 95 (suppl.): S37–43. 20. Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogs in clinical neuroscience 2008; 10: 329–36. 21. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9–15. 22. Olié JP, Emsley R.. Confirmed clinical efficacy of agomelatine (25–50 mg) in major depression: two randomized, doubl-blind, placebo-controlled studies. Eur Neuropsychopharmacol 15: 416. 23. Olie JР, Kasper S. Efficacy of agomelatine, а МТ1/МТ2-receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10 (5): 661–73. 24. Quera-Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691–6. 25 Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978; 8: 325–9. 26. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995; 17: 786–90. 27. Reynolds CF 3rd. Sleep and affective disorders: a minireview. Psychiatr Clin North Am 1987; 10: 583–91. 28. Rosenberg RP. Sleep maintenance insomnia: strengths and weakness of current pharmacologic therapies. Ann Clin Psychiat 2006; 18: 49–56. 29. Spoormaker VI, van den Bout J. Depression and anxiety complaints: relations with sleep disturbances. Eur Psychiat 2005; 20: 243–5. 30. Staner L, Cornette F, Maurice D et al. Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia. J Sleep Res 2003; 12: 319–30. 31. Van Reeth O, Weibel L, Olivares E et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1582–91. 32.Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927–47. 33.Winokur A, Gary KA, Rodner S et al. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001; 14: 19–28. 34. Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogs in clinical neuroscience 2008; 10: 337–44.